More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.30B
EPS
2.24
P/E ratio
4.8
Price to sales
3.48
Dividend yield
--
Beta
0.376069
Previous close
$18.49
Today's open
$18.39
Day's range
$18.28 - $18.58
52 week range
$18.28 - $25.15
show more
CEO
Pavel Raifeld
Employees
159
Headquarters
Burlingame, CA
Exchange
Nasdaq Global Select
Shares outstanding
71081477
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Replenish Your Portfolio With These 5 Low Price-to-Sales Stocks
Low P/S ratios, solid fundamentals and manageable debt can help uncover undervalued stocks with upside potential. Explore INVA, DINO, PARR, GPRE and PBF.
Zacks Investment Research • Nov 11, 2026

Is Innoviva (INVA) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks Investment Research • Nov 10, 2026

INVA or MRK: Which Is the Better Value Stock Right Now?
Investors with an interest in Large Cap Pharmaceuticals stocks have likely encountered both Innoviva (INVA) and Merck (MRK). But which of these two stocks presents investors with the better value opportunity right now?
Zacks Investment Research • Nov 9, 2026

Innoviva Reports Third Quarter 2026 Financial Results; Highlights Recent Company Progress
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (IST), and a portfolio of strategic investments in healthcare assets, today reported financial results for the third quarter ended September 30, 2026, and highlighted select corporate progress and achievements. “IST delivered anoth.
Business Wire • Nov 4, 2026

Innoviva (INVA) Tops Q3 Earnings Estimates
Innoviva (INVA) came out with quarterly earnings of $0.5 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $1.08 per share a year ago.
Zacks Investment Research • Nov 5, 2026

Innoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics (IST), a subsidiary of Innoviva, Inc. (NASDAQ: INVA), announced today it will present data from four abstracts at IDWeek 2026, the annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS). The meeting will be held October 21–24, 2026, at the Walter E. Washington Conventio.
Business Wire • Oct 19, 2026

Do Options Traders Know Something About Innoviva Stock We Don't?
Investors need to pay close attention to INVA stock based on the movements in the options market lately.
Zacks Investment Research • Oct 12, 2026

Should Value Investors Buy Innoviva (INVA) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks Investment Research • Oct 8, 2026

5 Attractive Low Price-to-Sales Stocks With Promising Upside Potential
DINO, INVA, PARR, GNW and PBF stand out as low price-to-sales stocks with promising upside potential. Discover how attractive valuations can uncover hidden value.
Zacks Investment Research • Oct 8, 2026

INVA vs. MRK: Which Stock Is the Better Value Option?
Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Innoviva (INVA) or Merck (MRK). But which of these two stocks is more attractive to value investors?
Zacks Investment Research • Oct 8, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Innoviva Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.